Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $1,101.00 Consensus Price Target from Brokerages

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has received an average recommendation of “Moderate Buy” from the twenty-one brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $1,097.25.

Several research analysts have recently issued reports on the company. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday. Morgan Stanley decreased their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Truist Financial decreased their target price on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Barclays decreased their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, Royal Bank of Canada decreased their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st.

Regeneron Pharmaceuticals Trading Up 0.1 %

NASDAQ REGN opened at $829.43 on Wednesday. Regeneron Pharmaceuticals has a fifty-two week low of $783.57 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a 50 day simple moving average of $1,043.57 and a two-hundred day simple moving average of $1,039.92. The stock has a market cap of $91.44 billion, a P/E ratio of 20.53, a price-to-earnings-growth ratio of 2.90 and a beta of 0.15.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 7.48% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently made changes to their positions in REGN. SteelPeak Wealth LLC raised its position in Regeneron Pharmaceuticals by 173.0% in the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after acquiring an additional 692 shares during the period. Atria Investments Inc lifted its position in Regeneron Pharmaceuticals by 12.2% during the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock valued at $8,317,000 after purchasing an additional 941 shares in the last quarter. Tri Locum Partners LP grew its holdings in Regeneron Pharmaceuticals by 104.5% during the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after purchasing an additional 8,949 shares during the period. Nordea Investment Management AB increased its position in Regeneron Pharmaceuticals by 23.2% in the first quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock worth $28,218,000 after buying an additional 5,495 shares in the last quarter. Finally, Tidal Investments LLC increased its position in Regeneron Pharmaceuticals by 16.8% in the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after buying an additional 711 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.